Non-Profit Co-Founded by Mayo to Make Affordable Insulin
Rochester, MN (KROC-AM News) - A non-profit company formed by the Mayo Clinic and six other hospitals has announced plans to begin manufacturing and distributing affordable insulin.
A Mayo Clinic news release says Civica Rx is a generic drug company and will be manufacturing insulin at a 140,000 square foot manufacturing plant that is under construction in Virginia. Eventually, Civica RX will make three types of insulin (glargine, lispro and aspart) that will be interchangeable with Lantus, Humalog, and Novolog. It is expected that glargine type insulin manufactured by the company will be available to consumers in 2024 pending FDA approval.
The manufacturing plant in Virginia is being designed to have the capacity to produce "a substantial amount of the insulin needed in the US, with additional space to increase production of necessary." The Mayo Clinic says the insulin products will be available in vials and prefilled pen cartridges.
"Mayo Clinic chose to be a founding member of this innovative venture because our leadership understood the positive impact its success would have on the health of patients and its potential to help solve some of the nation's biggest health care challenges," says Dennis Dahlen, Mayo Clinic's chief financial officer and a member of Civica's board of directors. "Civica’s announcement regarding generic insulin is a significant step toward ensuring patients with diabetes have access to this vital medication."
The news release says the plans announced by Civica RX call for the insulin products to sell at a significant discount. The plan recommends a maximum retail price of $30 for a vial of insulin and $55 for a box of five pen cartridges.
Minnesota Acupuncturist Accused of $1.6 million in Medicaid Fraud
$2.1 Million Dollar Pill Hill home in Rochester Features Secret Wine Cellar